Related Experiment Video
Updated: May 10, 2026
11:27
A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
A new alpha in line between KRAS and NF-κB activation?
1Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53705, USA.
Cancer Discovery
|June 11, 2013
Summary
Researchers discovered that GSK-3α, not GSK-3β, links KRAS to NF-κB signaling in pancreatic cancer. Inhibiting GSK-3α slowed tumor growth, identifying it as a potential therapeutic target for KRAS-positive pancreatic cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Oncogenic KRAS mutations drive pancreatic ductal adenocarcinoma (PDAC) progression.
- NF-κB signaling pathways are frequently activated in pancreatic cancer, promoting tumor growth and survival.
- GSK-3β is a well-studied kinase, but the role of GSK-3α in cancer remains less understood.
Purpose of the Study:
- To elucidate the role of GSK-3α in mediating the link between oncogenic KRAS and NF-κB activation in pancreatic cancer.
- To investigate the potential of targeting GSK-3α as a therapeutic strategy for KRAS-driven pancreatic cancer.
Main Methods:
- Utilized cell lines and in vivo models of pancreatic cancer.
- Investigated the interaction between GSK-3α, TAK1-TAB complexes, and NF-κB signaling.
- Assessed the effects of GSK-3α inhibition on pancreatic cancer cell proliferation and tumor growth.
Main Results:
- Identified GSK-3α, not GSK-3β, as a key mediator connecting oncogenic KRAS to both canonical and noncanonical NF-κB activation.
- Demonstrated that GSK-3α binds and stabilizes TAK1-TAB complexes, leading to constitutive activation of canonical NF-κB signaling.
- Showed that inhibition of GSK-3α significantly retards pancreatic cancer growth in vitro and in vivo.
Conclusions:
- GSK-3α plays a critical, previously unrecognized role in KRAS-driven pancreatic cancer by regulating NF-κB signaling.
- Targeting GSK-3α represents a promising therapeutic avenue for patients with KRAS-positive pancreatic cancer.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
02:26NF-kB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
02:04Co-activators and Co-repressors
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:45Regulation of Nuclear Protein Sorting
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...